載入...

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

PURPOSE: Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients with PAH have a deficiency of prostacyclin and prostacyclin synthase. Selexipag is an orally available and selective prostacyclin receptor (IP receptor) agonist. Selexipag...

全面介紹

Na minha lista:
書目詳細資料
發表在:Am J Cardiovasc Drugs
Main Authors: Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
格式: Artigo
語言:Inglês
出版: Springer International Publishing 2015
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4452035/
https://ncbi.nlm.nih.gov/pubmed/25850750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-015-0117-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!